Verbatim response from ChatGPT
Short answer
- Which works better: On average, tirzepatide (brand name Zepbound for weight loss) has produced larger mean weight losses in clinical trials than semaglutide 2.4 mg (Wegovy). Individual responses vary, though, and side effects differ.
- Which is easier to get online: Wegovy/semaglutide is currently easier to obtain through telehealth clinics and online pharmacies than Zepbound, because semaglutide products and telehealth prescribing pathways are more widely established. Zepbound (tirzepatide for weight) is newer and somewhat harder to find online, though some clinics may prescribe tirzepatide (often the diabetes brand Mounjaro) off‑label.
Key differences — efficacy, safety, and evidence
- Mechanism: Wegovy = semaglutide (GLP‑1 receptor agonist). Zepbound = tirzepatide (dual GIP + GLP‑1 agonist). Tirzepatide targets two pathways, which likely explains stronger weight effects in trials.
- Efficacy (clinical-trial averages): Wegovy (semaglutide 2.4 mg) produced roughly mid‑teens percent body‑weight loss on average in STEP trials. Tirzepatide (higher doses studied for obesity) produced larger average losses in SURMOUNT trials — often several percentage points more, with the highest tirzepatide dose producing weight losses in the high teens to low twenties percent range for many participants. (Exact results vary by study, dose and population.)
- Side effects: Both commonly cause gastrointestinal effects (nausea, vomiting, diarrhea, constipation). Tirzepatide may have a higher frequency or intensity of GI side effects at some doses. Both drugs have safety considerations (e.g., risk signals in rodent thyroid C‑cell studies; contraindications such as personal/family history of medullary thyroid carcinoma or MEN2). Rare but serious risks (pancreatitis, gallbladder disease) have been reported with GLP‑1/GIP drugs; discuss with your clinician.
- Long‑term and head‑to‑head data: Direct randomized head‑to‑head weight‑loss trials comparing Zepbound vs Wegovy are limited. The comparative advantage for tirzepatide comes mainly from separate large trials and indirect comparisons.
Availability online and insurance/cost
- Wegovy (semaglutide) is widely prescribed for weight loss by many telehealth services and obesity clinics. Because semaglutide (Ozempic) has been used for diabetes for longer and semaglutide retail supply chains are larger, telehealth platforms and local clinics more commonly offer it.
- Zepbound (tirzepatide for weight loss) is newer and may be harder to get through online clinics. Many clinicians have used tirzepatide’s diabetes brand (Mounjaro) off‑label for weight loss, but that is changing as Zepbound becomes the indicated product for weight management.
- Insurance: Most private health plans and Medicare typically do not cover these drugs for routine weight management (coverage is slowly changing). Out‑of‑pocket costs are high for both. Manufacturer savings programs may be available for eligible patients.
- Safety tip: Avoid buying injectables from unverified international or “black market” sites. Use licensed pharmacies and legitimate telehealth services.
Practical recommendations
- If your priority is maximal weight loss and you’re willing to accept possibly stronger GI side effects and closer medical monitoring, tirzepatide (Zepbound) is likely to be more effective on average.
- If you want something easier to obtain online and with a long track record for weight loss prescribing via telehealth, semaglutide (Wegovy or prescription semaglutide programs) is generally easier to access.
- Next steps: talk to your primary care doctor, an endocrinologist, or an ABOM‑certified obesity medicine clinician to review medical history, contraindications, and monitoring plan. If you prefer telehealth, reputable services that commonly evaluate and prescribe GLP‑1/GIP therapies include Calibrate, Hims/Hers, Ro, PlushCare, and specialty obesity clinics — check each service’s prescribing policies and state availability first.
If you’d like, I can:
- help you compare typical side‑effect profiles and monitoring needs in more detail,
- list telehealth providers that operate in your state and their typical offerings, or
- draft questions to bring to your clinician. Which would be most useful?